Histopathologic Consideration of Fiducial Gold Markers Inserted for Real-Time Tumor-Tracking Radiotherapy Against Lung Cancer

Journal Article · Fri Feb 01 00:00:00 EST 2008 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/j.ijrobp.2007.06.064· OSTI ID:21039743

Imura, Mikado; Yamazaki, Koichi ^[1]; Kubota, Kanako C; Itoh, Tomoo ^[2]; Onimaru, Rikiya ^[3]; Cho, Yasushi; Hida, Yasuhiro; Kaga, Kichizo ^[4]; Onodera, Yuya ^[3]; Ogura, Shigeaki ^[5]; Dosaka-Akita, Hirotoshi ^[6]; Shirato, Hiroki ^[3]; Nishimura, Masaharu ^[1]

---

1. First Department of Medicine, Hokkaido University School of Medicine, Sapporo (Japan)
2. Department of Surgical Pathology, Hokkaido University Hospital, Sapporo (Japan)
3. Department of Radiology, Hokkaido University School of Medicine, Sapporo (Japan)
4. Department of Surgical Oncology, Hokkaido University School of Medicine, Sapporo (Japan)
5. Department of Respiratory Diseases, Sapporo City General Hospital, Sapporo (Japan)
6. Department of Medical Oncology, Hokkaido University Graduate School of Medicine, Sapporo (Japan)

Purpose: Internal fiducial gold markers, safely inserted with bronchoscopy, have been used in real-time tumor-tracking radiotherapy for lung cancer. We investigated the histopathologic findings at several points after the insertion of the gold markers. Methods and Materials: Sixteen gold markers were inserted for preoperative marking in 7 patients who subsequently underwent partial resection of tumors by video-assisted thoracoscopic surgery within 7 days. Results: Fibrotic changes and hyperplasia of type 2 pneumocytes around the markers were seen 5 or 7 days after insertion, and fibrin exudation without fibrosis was detected 1 or 2 days after insertion. Conclusions: Because fibroblastic changes start approximately 5 days after gold marker insertion, real-time tumor-tracking radiotherapy should be started >5 days after gold marker insertion.

• OSTI ID: 21039743
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Vol. 70, Issue 2; Other Information: DOI: 10.1016/j.ijrobp.2007.06.064; PII: S0360-3016(07)01170-4; Copyright (c) 2008 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
CARCINOMAS
FIBRIN
FIBROSIS
LUNGS
PATIENTS
RADIOTHERAPY
SURGERY